W

ASHINGTON — When the Trump administration unveiled a new Medicare proposal this week to cut payments to hospitals as part of a drug reimbursement program, Health and Human Services Secretary Tom Price called the plan a “significant step toward fulfilling President Trump’s promise to address rising drug prices.”

It may not be that simple.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • If the drug companies didn’t advertise on TV and in magazines, they wouldn’t need to charge do much. The general public cannot but direct, so why market to public? Direct marketing to physicians, hospital, and trade magazines
    should be the only marketing drug companies are allowed.

  • Simple? Yes. When you are charged $100 for an antibiotic prescription in the USA and it is sold in India by the same company for $4, something is fishy. Subsidizing healthcare, big pharma, where does it end?

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.